Connect with us

Health

Post-Vax Clot Case Supports Angiomax Use – MedPage Today

This might be a good non-heparin alternative, docs say

Published

on

Article feature image

Bivalirudin (Angiomax) worked for one of the very rare cases of blood clots with low platelets after vaccination against COVID-19, researchers reported.
The 40-year-old woman presented with a headache on the same day that the CDC and FDA hit pause on use of the Johnson & Johnson vaccine over risk of what’s being dubbed vaccine-induced thrombotic thrombocytopenia (VITT) or thrombosis with thrombocytopenia syndrome (TTS).
She developed a headache, sinus pressure, myalgias, and sore throat with tonsillar…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Ovarian cancer: Setback as major screening trial fails to save lives – BBC News
Article feature image
Study: 80% of hospital COVID-19 patients have neurologic complications – CIDRAP